CTOs on the Move

Lee Pharmaceuticals

www.leepharmaceuticals.com

 
Lee Pharmaceuticals is an established manufacturer of quality lip balm, saline nasal spray and OTC products. We are aggressively pursuing the Private Label Lip Balm and OTC business with our products that are national brand equivalent.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

IMX Medical Management Services

IMX Medical Management Services is a Bala Cynwyd, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cytomation

Cytomation is a Fort Collins, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HealthTrio LLC

HealthTrio LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Haemoscope Corporation

Haemoscope Corporation is a Niles, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic